The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei-Reference-Cited by-同舟云学术

The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei

Published:2023-03-03 Issue:3 Volume:12 Page:506
ISSN:2079-6382
Container-title:Antibiotics
language:en
Short-container-title:Antibiotics

Author:

Nelson Michelle¹,Barnes Kay B.¹,Davies Carwyn H.¹,Cote Christopher K.²,Meinig J. Matthew²,Biryukov Sergei S.²,Dyer David N.²,Frick Ondraya²,Heine Henry³,Pfefferle Denise A.⁴,Horstman-Smith Amanda⁵,Barbaras Julie⁶,Harding Sarah V.¹⁷

Affiliation:

1. Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK

2. United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA

3. Institute for Therapeutic Innovation, University of Florida, Orlando, FL 32827, USA

4. Battelle Memorial Institute, Columbus, OH 43201, USA

5. Parsons Corporation, Centerville, VA 20120, USA

6. Defense Threat Reduction Agency, Fort Belvoir, VA 22060, USA

7. School of Respiratory Sciences, University of Leicester, Leicester LE1 7RH, UK

Abstract

Burkholderia pseudomallei, the causative agent of the disease melioidosis, has been isolated from the environment in 45 countries. The treatment of melioidosis is complex, requiring lengthy antibiotic regimens, which can result in the relapse of the disease following treatment cessation. It is important that novel therapies to treat infections with B. pseudomallei be assessed in appropriate animal models, and discussions regarding the different protocols used between laboratories are critical. A ‘deep dive’ was held in October 2020 focusing on the use of the BALB/c mouse model and the inhalational route of infection to evaluate new antibiotic therapies.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Link

https://www.mdpi.com/2079-6382/12/3/506/pdf

Reference55 articles.

1. Treatment and prophylaxis of melioidosis;Dance;Int. J. Antimicrob. Agents,2014

2. Pitman, M.C., Luck, T., Marshall, C.S., Anstey, N.M., Ward, L., and Currie, B.J. (2015). Intravenous therapy duration and outcomes in melioidosis: A new treatment paradigm. PLoS Negl. Trop. Dis., 9.

3. Sullivan, R.P., Marshall, C.S., Anstey, N.M., Ward, L., and Currie, B.J. (2020). 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl. Trop. Dis., 14.

4. Molecular epidemiology and antibiotic resistance of Burkholderia pseudomallei isolates from Hainan, China;Rao;Medicine,2019

5. Taking the next gen step: Comprehensive antimicrobial resistance detection from Burkholderia pseudomallei;Madden;Ebio Med.,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in Balb/c mice;Infection and Immunity;2024-03-12

2. Detection of low-level animal-to-animal transmission in BALB/c mouse models of melioidosis;Frontiers in Bacteriology;2023-11-06